Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 35, Issue 3, 2015, Pages 333-336

  Li, Chao lin ^a,b   Zhao, Lu jie ^c   Zhou, Xin li ^a   Wu, Hui xiao ^a   Zhao, Jia jun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Department of Endocrinology ^*  (China)

^c YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

dipeptidyl peptidase 4; glucagon like peptide 1 receptor agonists; insulin resistance; non alcoholic fatty liver disease; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; TRIACYLGLYCEROL;

AGONISTS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HUMAN; LIPID METABOLISM; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDES;

EID: 84931269488     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-015-1433-2     Document Type: Article

References (50)

1. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev, 2008,60(4):470–512
2. MacDonald PE, El-Kholy W, Riedel MJ, et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes, 2002,51(Suppl3):S434–S442
3. Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother, 2011,45(7–8):850–860
4. Madsbad S, Kielgast U, Asmar M, et al. An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab, 2011,13(5):394–407
5. Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev, 2006,22(6):483–491
6. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 2004,27(11): 2628–2635
7. Ahrén B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care, 2010,33(4):730–732
8. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab, 2006,91(11):4612–4619
9. Scheen AJ. DPP-4 inhibitors in the management of type 2diabetes: a critical review of head-to-head trials. Diabetes Metab, 2012,38(2):89–101
10. Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther, 2012,14(4):350–364
11. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis, 2004,8(3):501–519
12. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis, 2010,42(5):320–330
13. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med, 2008,75(10):721–728
14. Davis RC, Castellani LW, Hosseini M, et al. Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice. Diabetes, 2010,59(7):1616–1625
15. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab, 2011,96(4): 1093–1097
16. Chang Y, Ryu S, Sung E, et al. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem, 2007,53(4):686–692
17. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 2010,51(5):1584–1592
18. Shen Z, Liang X, Rogers CQ, et al. Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol, 2010,298(3):G364–G374
19. Hou X, Xu S, Maitland-Toolan KA, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem, 2008,283(29): 20015–20026
20. Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int, 2011,31(9):1285–1297
21. Miyazaki M, Kato M, Tanaka K, et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep, 2012,5(3):729–733
22. Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One, 2010,5(8):e12226
23. Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol, 2007,6(4):242–250
24. Ben-Shlomo S, Zvibel I, Shnell M, et al. Glucagonlike peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol, 2011,54(6):1214–1223
25. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes, 2011,60(4):1246–1257
26. Patel V, Joharapurkar A, Dhanesha N, et al. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1diabetic mice. Pharmacol Rep, 2013,65(4):927–936
27. Lee J, Hong SW, Chae SW, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J. PLos One, 2012,7(2):e31394
28. Dhanesha N, Joharapurkar A, Shah G, et al. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice. Eur J Pharmacol, 2013,714(1–3):188–192
29. He M, Su H, Gao W, et al. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice. PLoS One, 2010,5(12):e14205
30. Trevaskis JL, Griffin PS, Wittmer C, et al. Glucagon-like peptide-1 (GLP-1) receptor agonism improves metabolic, biochemical and histopathological indices of nonalcoholic steatohepatitis (NASH) in mice. Am J Physiol Gastrointest Liver Physio, 2012,302(8):G762–G772
31. Kawaguchi T, Itou M, Taniguchi E, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and delta-5-desaturase index in a murine model of non- alcoholic steatohepatitis. Int J Mol Med, 2014,34(3):782–787
32. Gupta NA, Kolachala VL, Jiang R, et al. The glucagon-like peptide-1 receptor agonist exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol, 2012,181(5):1693–1701
33. Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-Like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. hepatology, 2006,43(1):173–181
34. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE/mice. Endocrinology, 2013,154(1):127–139
35. Zhang L, Yang M, Ren H, et al. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int, 2013,33(5):794–804
36. Mells JE, Fu PP, Sharma S, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol, 2012,302(2):G225–G235
37. Parlevliet ET, Wang Y, Geerling JJ, et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE* 3-leiden mice. PLoS One, 2012,7(11):e49152
38. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin, 2008,24(1):275–286
39. Sathyanarayana P, Jogi M, Muthupillai R, et al. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring), 2011,19(12):2310–2315
40. Kenny PR, Brady DE, Torres DM, et al. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol, 2010,105(12):2707–2709
41. Ohki T, Isogawa A, Iwamoto M, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Sci World J, 2012,2012:496453
42. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther, 2013,37(2):234–242
43. Eguchi Y, Kitajima Y, Hyogo H, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolearance in Japanese patients (LEAN-J). Hepatol Res, 2015,45(3):269–278
44. Cuthbertson DJ, Irwin A, Gardner CJ, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-likepeptide-1 (GLP-1) receptor agonists. PLoS One, 2012,7 (12):e50117
45. Itou M, Kawaguchi T, Taniguchi E, et al. Dipeptidyl peptidase IV inhibitor improves insulin resistance and steatosis in a refractory nonalcoholic fatty liver disease patient: A case report. case Rep Gastroenterol, 2012,6(2):538–544
46. Kahal H, Abouda G, Rigby AS, et al. Glucagon like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and non-alcoholic fatty liver disease. Clin Endocrinol (Oxf), 2014,81(4):523–528
47. Iwasaki T, Yoneda M, Inamori M, et al. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology, 2011,58(112):2103–2105
48. Yilmaz Y, Yonal O, Deyneli O, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg, 2012,75(2):240–244
49. Samso SL, Bajaj M. Potential of incretin based therapies for non-alcoholic fatty liver disease. J Diabetes Complications, 2013,27(4):401–406
50. Fruci B, Giuliano S, Mazza A, et al. Nonalcoholic fatty liver: A possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci, 2013,14(11):22933–22966